Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Incyte Corp - Key Facts

Incyte Corp - Key Employees

Incyte Corp - Key Employee Biographies

Incyte Corp - Major Products and Services

Incyte Corp - History

Incyte Corp - Company Statement

Incyte Corp - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Incyte Corp - Business Description

Product Category: Iclusig

Performance

Product Category: Jakafi

Performance

Product Category: Jakavi Product Royalty Revenue

Performance

Product Category: Milestone and Contract Revenue

Performance

Product Category: Olumiant Product Royalty Revenues

Performance

Product Category: Other Revenue

Performance

R&D Overview

Incyte Corp - Corporate Strategy

Incyte Corp - SWOT Analysis

SWOT Analysis - Overview

Incyte Corp - Strengths

Incyte Corp - Weaknesses

Incyte Corp - Opportunities

Incyte Corp - Threats

Incyte Corp - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Incyte Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Incyte Corp, Recent Deals Summary

Section 5 – Company’s Recent Developments

Apr 01, 2019: Merus and Incyte Present MCLA-145 Program Preclinical Data

Apr 01, 2019: Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019

Mar 20, 2019: PRNewswire Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China December 16, 2018

Feb 28, 2019: Incyte Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2019

Jan 03, 2019: Incyte appoints Christiana Stamoulis as chief financial officer

Dec 18, 2018: Incyte agrees to licence three products to Innovent Biologics

Nov 27, 2018: Incyte names Dr. Dashyant Dhanak as Chief Scientific Officer

Nov 27, 2018: Incyte Appoints Dr. Dashyant Dhanak as Chief Scientific Officer

Nov 01, 2018: Multiple Abstracts Highlighting Data from Incyte’s Targeted Therapy Portfolio Accepted for Presentation at the 60th Annual ASH Meeting

Oct 25, 2018: FDA Grants Priority Review for Ruxolitinib (Jakafi ) as a Treatment for Patients with Acute Graft-Versus-Host Disease

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

Incyte Corp (INCY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Incyte Corp (Incyte) is a biopharmaceutical company that discovers, develops, and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycythemia vera who are intolerant to hydroxyurea. Jakafi is distributed principally through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Norvatis) develops and commercializes ruxolitinib outside the US for hematologic and oncologic indications under the name Jakavi. The company’s pipeline portfolio encompasses drug indications targeted at the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, multiple tumor types, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

Incyte Corp Key Recent Developments

Apr 01,2019 Merus and Incyte Present MCLA-145 Program Preclinical Data
Apr 01,2019 Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019
Mar 20,2019 PRNewswire Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China December 16, 2018
Feb 28,2019 Incyte Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2019

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company